DK1638574T3 - Nye farmaceutiske anvendelser af staurosporin-derivater - Google Patents

Nye farmaceutiske anvendelser af staurosporin-derivater

Info

Publication number
DK1638574T3
DK1638574T3 DK04740016.3T DK04740016T DK1638574T3 DK 1638574 T3 DK1638574 T3 DK 1638574T3 DK 04740016 T DK04740016 T DK 04740016T DK 1638574 T3 DK1638574 T3 DK 1638574T3
Authority
DK
Denmark
Prior art keywords
warm
pharmaceutical applications
new pharmaceutical
derivatives
staurosporin derivatives
Prior art date
Application number
DK04740016.3T
Other languages
English (en)
Inventor
Steven Coutre
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33539193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1638574(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1638574T3 publication Critical patent/DK1638574T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK04740016.3T 2003-06-18 2004-06-17 Nye farmaceutiske anvendelser af staurosporin-derivater DK1638574T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47957503P 2003-06-18 2003-06-18
PCT/EP2004/006562 WO2004112794A2 (en) 2003-06-18 2004-06-17 New pharmaceutical uses of staurosporine derivatives

Publications (1)

Publication Number Publication Date
DK1638574T3 true DK1638574T3 (da) 2010-08-02

Family

ID=33539193

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04740016.3T DK1638574T3 (da) 2003-06-18 2004-06-17 Nye farmaceutiske anvendelser af staurosporin-derivater

Country Status (24)

Country Link
US (2) US8575146B2 (da)
EP (1) EP1638574B1 (da)
JP (2) JP5057780B2 (da)
CN (2) CN100457111C (da)
AT (1) ATE464052T1 (da)
AU (1) AU2004248909B2 (da)
BE (1) BE2017C067I2 (da)
BR (1) BRPI0411563B8 (da)
CA (2) CA2527703C (da)
CY (2) CY1110179T1 (da)
DE (1) DE602004026578D1 (da)
DK (1) DK1638574T3 (da)
ES (1) ES2344700T3 (da)
FR (1) FR17C1063I2 (da)
HK (1) HK1095519A1 (da)
HU (1) HUS000503I2 (da)
LU (1) LUC00055I9 (da)
MX (1) MXPA05013722A (da)
NL (1) NL300917I2 (da)
PL (1) PL1638574T3 (da)
PT (1) PT1638574E (da)
SI (1) SI1638574T1 (da)
TW (1) TWI324604B (da)
WO (1) WO2004112794A2 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
US20060014165A1 (en) * 2003-07-14 2006-01-19 Decode Genetics Ehf. Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
WO2005049032A1 (en) 2003-11-18 2005-06-02 Novartis Ag Inhibitors of the mutant form of kit
WO2005115385A1 (en) * 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating acne
CN103251953A (zh) * 2004-07-19 2013-08-21 约翰·霍普金斯大学 供免疫抑制的flt3抑制剂
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
GB0419159D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
US20080176879A1 (en) * 2005-05-02 2008-07-24 Leila Alland Pyrimidylaminobenzamide Derivatives For Sytemic Mastocytosis
US8076321B2 (en) * 2005-07-20 2011-12-13 Peter Valent Compositions for treatment of systemic mastocytosis
CA2629478C (en) * 2005-11-14 2013-10-15 Universitat Zurich Staurosporine derivatives for use in alveolar rhabdomyosarcoma
WO2009092442A1 (en) * 2008-01-23 2009-07-30 Universidad De Barcelona Treatment of portal hypertension and related conditions by combined inhibition of the vegf and pdgf signalling pathways
EP2662078A1 (en) * 2010-11-10 2013-11-13 National Jewish Health Methods to Treat Allergic Conditions
CA3118330A1 (en) 2018-11-01 2020-05-07 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US11325978B2 (en) * 2018-11-06 2022-05-10 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for treating beta-globinopathies
US11839619B2 (en) * 2019-09-16 2023-12-12 The Regents Of The University Of California Methods for treatment of pediatric systemic mastocytosis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639455A (en) * 1984-10-02 1987-01-27 Key Pharmaceuticals, Inc. Means of aiding in the prevention of sudden infant death syndrome
JPH0826037B2 (ja) * 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
CA2046801C (en) 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
DE69229490T2 (de) * 1991-05-09 2000-02-17 Neurim Pharmaceuticals (1991) Ltd., Tel Aviv Melatonin enthaltende Arzneimittel
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
US6184217B1 (en) * 1996-06-25 2001-02-06 Cephalon, Inc. Use of K-252a derivative
US6093740A (en) 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
AU4423799A (en) * 1998-06-04 1999-12-20 Cornell Research Foundation Inc. Methods and agents for modulating the immune response and inflammation involvingmonocyte and dendritic cell membrane proteins
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
ATE301661T1 (de) * 2000-12-08 2005-08-15 Ortho Mcneil Pharm Inc Makroheterocyclische verbindungen als kinase inhibitoren
GB0108606D0 (en) 2001-04-05 2001-05-23 Novartis Ag Organic compounds
US20030091974A1 (en) * 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
ATE401079T1 (de) * 2001-06-29 2008-08-15 Ab Science Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
TWI302836B (en) * 2001-10-30 2008-11-11 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
US6998391B2 (en) * 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
WO2004091663A1 (ja) 2003-04-18 2004-10-28 Kyowa Hakko Kogyo Co., Ltd. 神経再生薬
US20070037882A1 (en) 2003-04-22 2007-02-15 Astellas Pharma Inc. Remedy for cerebral neurodegenerative diseases using ppar agonist
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
WO2005049032A1 (en) 2003-11-18 2005-06-02 Novartis Ag Inhibitors of the mutant form of kit

Also Published As

Publication number Publication date
HK1095519A1 (en) 2007-05-11
JP5057780B2 (ja) 2012-10-24
CY1110179T1 (el) 2015-01-14
CA2527703A1 (en) 2004-12-29
CY2017048I2 (el) 2018-09-05
SI1638574T1 (sl) 2010-08-31
PL1638574T3 (pl) 2010-09-30
BE2017C067I2 (da) 2023-08-09
NL300917I2 (nl) 2018-01-09
AU2004248909B2 (en) 2008-05-08
CY2017048I1 (el) 2018-09-05
US20070299049A1 (en) 2007-12-27
WO2004112794A2 (en) 2004-12-29
US8575146B2 (en) 2013-11-05
HUS000503I2 (hu) 2021-03-29
US20130289018A1 (en) 2013-10-31
LUC00055I1 (da) 2017-12-14
FR17C1063I1 (da) 2018-02-16
EP1638574B1 (en) 2010-04-14
CN1805749A (zh) 2006-07-19
ES2344700T3 (es) 2010-09-03
CA2785950A1 (en) 2004-12-29
NL300917I1 (nl) 2017-12-12
AU2004248909A1 (en) 2004-12-29
LUC00055I2 (da) 2018-02-21
BRPI0411563B8 (pt) 2021-05-25
BRPI0411563B1 (pt) 2019-09-24
PT1638574E (pt) 2010-07-14
CN100457111C (zh) 2009-02-04
LUC00055I9 (da) 2022-11-09
JP2006527727A (ja) 2006-12-07
CA2527703C (en) 2012-10-23
BRPI0411563A (pt) 2006-08-01
HUS1700053I1 (hu) 2018-01-29
CN101164539A (zh) 2008-04-23
JP2012144572A (ja) 2012-08-02
WO2004112794A3 (en) 2005-06-16
TWI324604B (en) 2010-05-11
EP1638574A2 (en) 2006-03-29
DE602004026578D1 (de) 2010-05-27
ATE464052T1 (de) 2010-04-15
MXPA05013722A (es) 2006-03-08
FR17C1063I2 (fr) 2019-05-03
TW200512213A (en) 2005-04-01

Similar Documents

Publication Publication Date Title
FR17C1063I2 (fr) Nouvelle utilisation de derives de staurosporine
NO20055216D0 (no) Nye hydroksamater som terapeutiske midler
DE60140814D1 (de) N-phenyl-2-pyrimidine-amine derivatives
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
EA200800798A1 (ru) Фармацевтические композиции, предназначенные для лечения нарушений внутреннего уха
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
NO20084328L (no) Nye forbindelser
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
NO20092737L (no) Substituerte pyrazolo-kinazolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som kinase-inhibitorer
NO20085100L (no) Nye forbindelser
EA200971053A1 (ru) Способы лечения кожных язв
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
BRPI0410727A (pt) composto, composição farmacêutica, e, uso de um composto
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
ATE529417T1 (de) 3',4',5-trimethoxyflavonderivate als die schleimsekretion stimulierendes mittel, entsprechendes verfahren und pharmazeutische zusammensetzung, die diese enthält
BR0313718A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto
NO20065551L (no) Anvendelse av opoid reseptor antagonistforbindelser for forhindring og/eller behandling av sykdommer assosiert med malet calcineurin
TH401002069A (th) การใช้แบบใหม่ของอนุพันธ์สเทาโรสพอรีน